首页> 外国专利> MONITORING OF CARDIAC NATRIURETIC PEPTIDES DURING DIAGNOSIS, MANAGMENT, AND TREATMENT OF CARDIAC DISEASES

MONITORING OF CARDIAC NATRIURETIC PEPTIDES DURING DIAGNOSIS, MANAGMENT, AND TREATMENT OF CARDIAC DISEASES

机译:诊断,管理和治疗心脏疾病期间对心脏利钠肽的监测

摘要

In a cardiac monitoring method, at east an inactive natriuretic peptide ( 22 ) and an active natriuretic peptide ( 20 ) are assayed in a biological sample taken from a patient. Both the inactive and active natriuretic peptides are produced in the patient responsive to cardiac stress. A therapeutic agent ( 26 ), such as a synthetic or mimetic natriuretic peptide, is administered to the patient. The administered therapeutic agent substantially interferes with the active natriuretic peptide assay but does not substantially interfere with the inactive natriuretic peptide assay. Kinetics of the administered therapeutic agent are determined based on at least the active natriuretic peptide assay. Cardiac diagnostic information is determined based on at least the inactive natriuretic peptide assay.
机译:在心脏监测方法中,在东部,在取自患者的生物样品中测定了非活性利钠肽(22)和活性利钠肽(20)。响应心脏压力在患者体内产生无活性和有活性的利钠肽。诸如合成或模拟利钠肽的治疗剂(26)被施用于患者。所施用的治疗剂基本上干扰活性利钠肽测定,但基本上不干扰非利尿钠肽测定。至少基于活性利钠肽测定法来确定所给予的治疗剂的动力学。至少基于非活性利钠肽测定法来确定心脏诊断信息。

著录项

  • 公开/公告号EP1913402B1

    专利类型

  • 公开/公告日2017-10-25

    原文格式PDF

  • 申请/专利权人 KONINKLIJKE PHILIPS N.V.;

    申请/专利号EP20060780226

  • 发明设计人 SEHER JENS-PETER;PLUSKAL MALCOLM G.;

    申请日2006-07-27

  • 分类号G01N33/68;G01N33/74;

  • 国家 EP

  • 入库时间 2022-08-21 14:07:41

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号